Literature DB >> 25138236

Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011.

Anna K Holl1, Renate Grohmann, Martin Letmaier, Annamaria Painold, Sabrina Mörkl, Sermin Toto, Siegfried Kasper.   

Abstract

Over the past years, international treatment guidelines have been established for the treatment of anxiety disorders. Nevertheless, little is known as to whether the actual inpatient treatment follows these guidelines. The main goal of this study was to answer the question whether patients with anxiety disorder are treated according to treatment guidelines. A total of 2,573 psychiatric inpatients with the diagnosis of anxiety disorder (920 men, 1,653 women) were identified on the basis of the data of the international drug safety programme in psychiatry AMSP. Of these patients, 25.3% presented with phobia, 26.6% with panic disorder, 18.7% with generalized anxiety disorder (GAD), and 29.4% with other diagnoses of anxiety. In all of the patients, 12.7% did not receive any psychotropic medication and 22.9% were not treated with antidepressants. Only 59.3% of patients with GAD, 73.9% of patients with panic disorder, and 52.1% of patients with phobia were treated according to diagnostic guidelines. The majority (60.3%) of all patients received one or two psychotropic drugs, and only 3.7% received five or more psychotropic drugs. In two groups of patients (one group with phobia and one with panic disorder), the annual prescription rate of antidepressants significantly increased over time. The prescription rate for anticonvulsants in patients with GAD increased from 0% in 1997 to 41.7% in 2011, and for antipsychotics, from 40.7% in 1997 to 47.2% in 2011. In particular, patients with GAD were commonly treated with antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25138236     DOI: 10.1007/s00406-014-0523-7

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  39 in total

Review 1.  The AMSP drug safety program: methods and global results.

Authors:  R Grohmann; R R Engel; E Rüther; H Hippius
Journal:  Pharmacopsychiatry       Date:  2004-03       Impact factor: 5.788

2.  Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.

Authors:  Borwin Bandelow; Leo Sher; Robertas Bunevicius; Eric Hollander; Siegfried Kasper; Joseph Zohar; Hans-Jürgen Möller
Journal:  Int J Psychiatry Clin Pract       Date:  2012-04-30       Impact factor: 1.812

3.  The effect of citalopram in panic disorder.

Authors:  A G Wade; U Lepola; H J Koponen; V Pedersen; T Pedersen
Journal:  Br J Psychiatry       Date:  1997-06       Impact factor: 9.319

4.  Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen M Stahl; Ivan Gergel; Dayong Li
Journal:  J Clin Psychiatry       Date:  2003-11       Impact factor: 4.384

5.  Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.

Authors:  Borwin Bandelow; Guy Chouinard; Julio Bobes; Antti Ahokas; Ivan Eggens; Sherry Liu; Hans Eriksson
Journal:  Int J Neuropsychopharmacol       Date:  2009-08-20       Impact factor: 5.176

6.  Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders.

Authors:  C Spindelegger; R Lanzenberger; W Wadsak; L K Mien; P Stein; M Mitterhauser; U Moser; A Holik; L Pezawas; K Kletter; S Kasper
Journal:  Mol Psychiatry       Date:  2008-03-25       Impact factor: 15.992

7.  Differential treatment of phobias: use of imipramine for panic attacks.

Authors:  C M Zitrin
Journal:  J Behav Ther Exp Psychiatry       Date:  1983-03

8.  Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study.

Authors:  Sandeep Vaishnavi; Syed Alamy; Wei Zhang; Kathryn M Connor; Jonathan R T Davidson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-07-04       Impact factor: 5.067

9.  A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder.

Authors:  U M Lepola; A G Wade; E V Leinonen; H J Koponen; J Frazer; I Sjödin; J T Penttinen; T Pedersen; H J Lehto
Journal:  J Clin Psychiatry       Date:  1998-10       Impact factor: 4.384

10.  Suicidal ideation and suicide attempts in panic disorder and attacks.

Authors:  M M Weissman; G L Klerman; J S Markowitz; R Ouellette
Journal:  N Engl J Med       Date:  1989-11-02       Impact factor: 91.245

View more
  2 in total

1.  Psychiatrists' self-stigma, the DGPPN guideline for psychosocial interventions, and contemporary treatment strategies.

Authors:  Daniela Reich-Erkelenz; Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-04       Impact factor: 5.270

2.  Pharmacotherapy of psychiatric inpatients with adjustment disorder: current status and changes between 2000 and 2016.

Authors:  Timo Greiner; Beatrice Haack; Sermin Toto; Stefan Bleich; Renate Grohmann; Frank Faltraco; Martin Heinze; Michael Schneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-22       Impact factor: 5.270

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.